Priority review for cemdisiran addresses adult anti-AChR–positive gMG, leveraging a priority review voucher and aligning US and EU regulatory timelines through 2027. RNAi-mediated C5 suppression ...
In the autoimmune disorder myasthenia gravis (MG), the nicotinic acetylcholine receptors (nAChRs) are the primary targets of pathogenic antibodies. While MG mechanisms have been extensively studied in ...
Stacker has curated a gallery of the 50 college majors that go on to earn workers the most money. Results show a stark ...
Vascular inflammation triggers endothelial dysfunction, a pivotal factor in the pathogenesis of diabetic vascular complications. Complement component 1q (C1q), a crucial component of the immune system ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Forbes contributors publish independent expert analyses and insights. Gary Drenik is a writer covering AI, analytics and innovation. The AI return on investment debate is largely over. Companies are ...
What Is Empaveli, and Why Does It Matter? First approved in 2021 for a rare blood disorder, Empaveli (pegcetacoplan) is now approved as the first targeted medicine for adults and children aged 12 ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
A comprehensive Vue 3 Calendar component with Vuetify 3, TypeScript, and advanced features including drag & drop, lazy loading, filtering, and multiple view modes. The following code snippets show a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results